Prediction of Response to Docetaxel by Immunohistochemical Analysis of CYP3A4 Expression in Human Breast Cancers

DOI Web Site PubMed 3 Citations 21 References
  • Miyoshi Yasuo
    Department of Surgical Oncology, Osaka University Graduate School of Medicine
  • Taguchi Tetsuya
    Department of Surgical Oncology, Osaka University Graduate School of Medicine
  • Kim Seung Jin
    Department of Surgical Oncology, Osaka University Graduate School of Medicine
  • Tamaki Yasuhiro
    Department of Surgical Oncology, Osaka University Graduate School of Medicine
  • Noguchi Shinzaburo
    Department of Surgical Oncology, Osaka University Graduate School of Medicine

Search this article

Abstract

Background: Docetaxel (DOC) is inactivated by CYP3A4, high expression of which in tumor tissue might serve as a resistance mechanism. In the present study, the CYP3A4 protein level in breast cancers was determined by immunohistochemistry, and its relationship with the response to DOC treatment was studied.<br>Materials and Methods: Thirty-one patients with locally advanced (n = 21) or recurrent (n = 10) breast cancers underwent tumor biopsy, followed by DOC treatment (60 mg/m2 q3w). Expression of CYP3A4 was studied by immunohistochemistry.<br>Results: Patients with CYP3A4 negative tumors (n = 15) by immunohistochemistry showed a significantly (P < 0.01) higher response rate (67%) to DOC treatment than those with CYP3A4 positive tumors (n = 16, 19%). The positive predictive value, negative predictive value, and diagnostic accuracy of CYP3A4 expression by immunohistochemistry in the prediction of response to DOC were 67%, 81%, and 74%, respectively.<br>Conclusion: Immunohistochemical analysis of CYP3A4 expression in tumor cells might be clinically useful in the prediction of tumor response to DOC.

Journal

  • Breast Cancer

    Breast Cancer 12 (1), 11-15, 2005

    The Japanese Breast Cancer Society

Citations (3)*help

See more

References(21)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top